| Manufacturer | Eli Lilly and Company | Eli Lilly and Company |
| Pricing | Manufacturer self-pay options: - Starting Dose: $299/month for 2.5 mg through eligible KwikPen or vial self-pay programs.
- 5 mg Dose: $399/month through eligible self-pay options.
- Higher Doses: As low as $449/month for 7.5 mg, 10 mg, 12.5 mg, or 15 mg with the Zepbound Self Pay Journey Program.
- Program Requirements: Higher-dose promotional pricing requires eligible refills within 45 days; otherwise, regular prices may apply.
Retail prices may be higher. | Manufacturer pricing and savings: - Self-Pay Price: Starting at $499/month through eligible LillyDirect purchasing options.
- Available Doses: Self-pay offers apply to listed doses from 2.5 mg through 15 mg, subject to program terms.
- Insurance Savings: Eligible commercially insured patients with coverage may pay as little as $25 for a qualifying prescription.
Actual pharmacy prices may vary. |
| Insurance Coverage | - Commercial Insurance: Some plans cover Zepbound for eligible patients with obesity or other approved indications.
- Prior Authorization: BMI, weight-related conditions, and medical documentation may be required.
- Medicare: Coverage depends on the approved indication, applicable program rules, and individual plan. Some patients may qualify for the Medicare GLP-1 Bridge program.
- Diabetes Alone: Zepbound is not specifically approved for type 2 diabetes treatment.
| - Commercial Insurance: Many plans cover Mounjaro for eligible patients with type 2 diabetes.
- Medicare Part D: Coverage may be available for eligible beneficiaries with type 2 diabetes.
- Prior Authorization: A diabetes diagnosis and supporting medical documentation may be required.
- Weight Loss Alone: Generally not covered because Mounjaro is not approved specifically for weight management.
|
| Main Purpose | Long-term weight loss and weight maintenance in eligible adults with obesity or overweight. | Improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes. |
| Secondary Purposes | - Sleep Apnea: Treat moderate to severe obstructive sleep apnea in adults with obesity.
- Metabolic Health: May improve blood sugar regulation and other metabolic measures.
| - Cardiovascular Protection: Reduce major cardiovascular events in eligible adults with type 2 diabetes at high cardiovascular risk.
- Weight Reduction: May produce substantial weight loss as an additional treatment effect, although chronic weight management is not an approved Mounjaro indication.
|
| Active Ingredient | Tirzepatide, a dual GIP and GLP-1 receptor agonist. | Tirzepatide, a dual GIP and GLP-1 receptor agonist. The same active ingredient as Zepbound. |
| Benefits | - Weight Loss: Produces substantial average weight reduction in eligible adults.
- Appetite Regulation: Helps reduce hunger and food intake.
- Metabolic Health: May improve weight-related metabolic measures.
- Sleep Apnea: Reduces obstructive sleep apnea severity in eligible adults with obesity.
| - Blood Sugar Control: Produces substantial reductions in blood glucose and HbA1c.
- Weight Loss: Can produce clinically meaningful weight reduction in patients with type 2 diabetes.
- Appetite Regulation: Helps reduce hunger and food intake.
- Cardiovascular Health: Reduces major cardiovascular events in eligible adults with type 2 diabetes at high cardiovascular risk.
|
| Potential Health Risks | - Pancreatitis: Potential acute pancreatic inflammation.
- Gallbladder Problems: Including gallstones and gallbladder inflammation.
- Kidney Injury: Possible dehydration-related acute kidney injury.
- Gastrointestinal Reactions: Potentially severe digestive symptoms.
- Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
| - Pancreatitis: Potential acute pancreatic inflammation.
- Gallbladder Problems: Including gallstones and gallbladder inflammation.
- Kidney Injury: Possible dehydration-related acute kidney injury.
- Eye Complications: Diabetic retinopathy requires appropriate monitoring.
- Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
|
| Weight Loss Potential | In a 72-week clinical trial involving adults without diabetes, average body-weight reduction was approximately 15.0% with 5 mg, 19.5% with 10 mg, and 20.9% with 15 mg. Results vary by dosage and patient population. | In the SURPASS-2 trial involving adults with type 2 diabetes, tirzepatide produced approximately 7.6–11.2 kg (17–25 lb) of average weight loss over 40 weeks, depending on dose. Mounjaro is not approved specifically for weight management. |
| Administration | - Injection: Subcutaneous injection once weekly.
- Injection Sites: Abdomen, thigh, or upper arm.
- Available Forms: Single-dose pens, single-dose vials, and single-patient-use KwikPen presentations.
| - Injection: Subcutaneous injection once weekly.
- Injection Sites: Abdomen, thigh, or upper arm.
- Available Forms: Prefilled injection pens, including available multidose pen presentations.
|
| Dosing Considerations | - Starting Dose: Typically 2.5 mg weekly for 4 weeks.
- Dose Escalation: Increase to 5 mg weekly, with additional 2.5 mg increases after at least 4 weeks at the current dose when appropriate.
- Weight Management Maintenance: 5 mg, 10 mg, or 15 mg weekly.
- Sleep Apnea Maintenance: 10 mg or 15 mg weekly.
- Maximum Dose: 15 mg weekly.
| - Starting Dose: Typically 2.5 mg weekly for 4 weeks.
- Dose Escalation: Increase to 5 mg weekly, with additional 2.5 mg increases after at least 4 weeks at the current dose when appropriate.
- Maintenance Dosing: Individualized according to blood sugar response and tolerability.
- Maximum Adult Dose: 15 mg weekly.
|
| Who May Benefit Most? | Adults with obesity or qualifying overweight who need long-term weight management, including eligible patients with obesity-related obstructive sleep apnea. | Patients aged 10 years and older with type 2 diabetes who need improved blood sugar control, including adults who may benefit from additional weight loss or meet its cardiovascular risk-reduction indication. |
| How Fast Does It Work? | - Appetite: Changes may begin within the first several weeks.
- Initial Weight Loss: May become noticeable within several weeks.
- Substantial Weight Loss: Generally develops over several months, with major trials assessing outcomes at approximately 72 weeks.
- Sleep Apnea: Major clinical trials assessed improvements after 52 weeks.
| - Blood Sugar: Improvements may begin within the first weeks of treatment.
- HbA1c: Meaningful reductions generally develop over several weeks to months.
- Weight Loss: May begin within several weeks and continue over subsequent months.
|
| Potential Side Effects | - Digestive: Nausea, diarrhea, vomiting, constipation, abdominal discomfort, and indigestion.
- Other Effects: Fatigue, hair loss, and injection-site reactions.
- Timing: Gastrointestinal symptoms frequently occur during dose escalation.
| - Digestive: Nausea, diarrhea, vomiting, constipation, abdominal discomfort, and indigestion.
- Other Effects: Decreased appetite and possible injection-site reactions.
- Timing: Gastrointestinal symptoms frequently occur during dose escalation.
|